Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Lilly Japan Pitching Unique Benefits of Kisunla with AD Drug Now on Market
December 2, 2024
-
REGULATORY Japan Cabinet OKs Extra Budget, 44 Billion Yen for Pharma Measures
December 2, 2024
-
REGULATORY MOF Panel Urges Annual Price Revisions on All Drugs in 2025 Budget Proposal
November 29, 2024
-
REGULATORY Japan to Require Drug Makers to Set Up Legal Post of “Stable Supply Manager”
November 29, 2024
-
REGULATORY Japan Set to Put Up 100 Billion Yen to Support Pharma under Economic Package
November 29, 2024
-
REGULATORY DPP Confirms Plan to Urge 4 Ministers to Scrap Off-Year Price Revisions
November 28, 2024
-
COMMENTARY MOF Stands Pat with Off-Year Revisions despite Change in Politics, Does this Hint at Govt’s Reform Directions?
November 27, 2024
-
BUSINESS Shionogi Chided for Violating Promotion Guidelines with Actair
November 27, 2024
-
REGULATORY Japan Gets Down to the Business of Solving Drug Loss, New Scheme Begins with 78 Meds
November 26, 2024
-
REGULATORY Japan’s New Economic Package Covers Pharma-Related Steps, but Not Repeal of Off-Year Revisions
November 25, 2024
-
REGULATORY Pharma Renews Call for Abolishing Off-Year Revisions, but MHLW Stays Put with Honebuto
November 22, 2024
-
BUSINESS Genmab Japan to Expand into Solid Tumors, Boost Focus on Gyn/Onc: Chief
November 22, 2024
-
REGULATORY 3 Parties Reach Deal on Economic Plan, Off-Year “Abolition” Not Spelled Out
November 21, 2024
-
BUSINESS 25 Japan Drug Makers See 50% Growth in Operating Profit on FX, Unprofitability Re-Pricing
November 20, 2024
-
REGULATORY DPP Leader Poised to Urge 4 Ministers to Abolish Off-Year Revisions
November 20, 2024
-
ORGANIZATION Chuikyo Payer Rep Touts Necessity of FY2025 Off-Year Price Revision
November 19, 2024
-
REGULATORY Qalsody, Zepbound, Zeposia Up for Advisory Panel Review on Dec. 2
November 19, 2024
-
REGULATORY Pediatric Forms of Jakavi, More Drugs to Get Listing; Eylea Biosimilar Not on Roster
November 19, 2024
-
REGULATORY DPP Prods Ruling Camp to Be More Specific on Off-Year Revision in Economic Plan
November 19, 2024
-
BUSINESS Pfizer Japan Taps COO Hiroo Igarashi as New Skipper
November 18, 2024
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…